sgmo-20200930
false2020Q30001001233--12-31us-gaap:AccountingStandardsUpdate201801MemberP5Y00010012332020-01-012020-09-30xbrli:shares00010012332020-10-30iso4217:USD00010012332020-09-3000010012332019-12-3100010012332020-07-012020-09-3000010012332019-07-012019-09-3000010012332019-01-012019-09-30iso4217:USDxbrli:shares0001001233us-gaap:CommonStockMember2020-06-300001001233us-gaap:AdditionalPaidInCapitalMember2020-06-300001001233us-gaap:RetainedEarningsMember2020-06-300001001233us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001001233us-gaap:NoncontrollingInterestMember2020-06-3000010012332020-06-300001001233us-gaap:CommonStockMember2020-07-012020-09-300001001233us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001001233us-gaap:NoncontrollingInterestMember2020-07-012020-09-300001001233us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001001233us-gaap:RetainedEarningsMember2020-07-012020-09-300001001233us-gaap:CommonStockMember2020-09-300001001233us-gaap:AdditionalPaidInCapitalMember2020-09-300001001233us-gaap:RetainedEarningsMember2020-09-300001001233us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001001233us-gaap:NoncontrollingInterestMember2020-09-300001001233us-gaap:CommonStockMember2019-12-310001001233us-gaap:AdditionalPaidInCapitalMember2019-12-310001001233us-gaap:RetainedEarningsMember2019-12-310001001233us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001001233us-gaap:NoncontrollingInterestMember2019-12-310001001233us-gaap:CommonStockMember2020-01-012020-09-300001001233us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300001001233us-gaap:NoncontrollingInterestMember2020-01-012020-09-300001001233us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300001001233us-gaap:RetainedEarningsMember2020-01-012020-09-300001001233us-gaap:CommonStockMember2019-06-300001001233us-gaap:AdditionalPaidInCapitalMember2019-06-300001001233us-gaap:RetainedEarningsMember2019-06-300001001233us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-300001001233us-gaap:NoncontrollingInterestMember2019-06-3000010012332019-06-300001001233us-gaap:CommonStockMember2019-07-012019-09-300001001233us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-300001001233us-gaap:NoncontrollingInterestMember2019-07-012019-09-300001001233us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300001001233us-gaap:RetainedEarningsMember2019-07-012019-09-300001001233us-gaap:CommonStockMember2019-09-300001001233us-gaap:AdditionalPaidInCapitalMember2019-09-300001001233us-gaap:RetainedEarningsMember2019-09-300001001233us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-300001001233us-gaap:NoncontrollingInterestMember2019-09-3000010012332019-09-300001001233us-gaap:CommonStockMember2018-12-310001001233us-gaap:AdditionalPaidInCapitalMember2018-12-310001001233us-gaap:RetainedEarningsMember2018-12-310001001233us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310001001233us-gaap:NoncontrollingInterestMember2018-12-3100010012332018-12-3100010012332019-01-012019-03-310001001233us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-12-310001001233srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-12-310001001233us-gaap:CommonStockMember2019-01-012019-09-300001001233us-gaap:AdditionalPaidInCapitalMember2019-01-012019-09-300001001233us-gaap:NoncontrollingInterestMember2019-01-012019-09-300001001233us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-300001001233us-gaap:RetainedEarningsMember2019-01-012019-09-300001001233sgmo:ChangeInCollaborationAgreementScopeMembersgmo:PfizerMemberus-gaap:CollaborativeArrangementMember2020-07-012020-09-300001001233sgmo:PfizerAndSanofiMembersgmo:ChangeInCollaborationAgreementScopeMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-30xbrli:pure0001001233sgmo:PfizerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-09-300001001233sgmo:PfizerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2019-07-012019-09-300001001233sgmo:PfizerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300001001233sgmo:PfizerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-09-300001001233us-gaap:SalesRevenueNetMembersgmo:BiogenMAIncMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-09-300001001233us-gaap:SalesRevenueNetMembersgmo:BiogenMAIncMemberus-gaap:CustomerConcentrationRiskMember2019-07-012019-09-300001001233us-gaap:SalesRevenueNetMembersgmo:BiogenMAIncMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300001001233us-gaap:SalesRevenueNetMembersgmo:BiogenMAIncMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-09-300001001233us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembersgmo:KitePharmaIncMember2020-07-012020-09-300001001233us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembersgmo:KitePharmaIncMember2019-07-012019-09-300001001233us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembersgmo:KitePharmaIncMember2020-01-012020-09-300001001233us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembersgmo:KitePharmaIncMember2019-01-012019-09-300001001233us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembersgmo:SanofiMember2020-07-012020-09-300001001233us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembersgmo:SanofiMember2019-07-012019-09-300001001233us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembersgmo:SanofiMember2020-01-012020-09-300001001233us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembersgmo:SanofiMember2019-01-012019-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMember2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:AssetBackedSecuritiesMember2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:AssetBackedSecuritiesMember2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2020-09-300001001233sgmo:FreeSharesAssetMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-300001001233sgmo:FreeSharesAssetMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-300001001233sgmo:FreeSharesAssetMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-09-300001001233sgmo:FreeSharesAssetMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-09-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2019-12-310001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2019-12-310001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2019-12-310001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2019-12-310001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2019-12-310001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2019-12-310001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2019-12-310001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2019-12-310001001233us-gaap:FairValueMeasurementsRecurringMember2019-12-310001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2019-12-310001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2019-12-310001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2019-12-310001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2019-12-310001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2019-12-310001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2019-12-310001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2019-12-310001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2019-12-310001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2019-12-310001001233sgmo:FreeSharesAssetMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001001233sgmo:FreeSharesAssetMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310001001233sgmo:FreeSharesAssetMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310001001233sgmo:FreeSharesAssetMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2019-12-310001001233sgmo:SharePurchaseAgreementAndTenderOfferAgreementMembersgmo:SangamoFranceMember2018-07-200001001233sgmo:SharePurchaseAgreementAndTenderOfferAgreementMembersgmo:SangamoFranceMember2019-01-012019-12-310001001233sgmo:SharePurchaseAgreementAndTenderOfferAgreementMembersgmo:SangamoFranceMember2020-01-012020-09-300001001233sgmo:SharePurchaseAgreementAndTenderOfferAgreementMembersgmo:SangamoFranceMember2020-07-012020-09-300001001233sgmo:SharePurchaseAgreementAndTenderOfferAgreementMembersgmo:SangamoFranceMember2019-12-310001001233us-gaap:MeasurementInputSharePriceMember2020-09-300001001233us-gaap:MeasurementInputSharePriceMember2019-12-31iso4217:EURxbrli:shares0001001233us-gaap:MeasurementInputSharePriceMembersgmo:SangamoFranceMember2020-09-300001001233us-gaap:MeasurementInputSharePriceMembersgmo:SangamoFranceMember2019-12-310001001233sgmo:MeasurementInputExchangeRateMember2020-09-300001001233sgmo:MeasurementInputExchangeRateMember2019-12-310001001233sgmo:MeasurementInputStockPriceCorrelationMembersgmo:SangamoFranceMember2020-09-300001001233sgmo:MeasurementInputStockPriceCorrelationMembersgmo:SangamoFranceMember2019-12-310001001233us-gaap:MeasurementInputOptionVolatilityMember2020-09-300001001233us-gaap:MeasurementInputOptionVolatilityMember2019-12-310001001233sgmo:SangamoFranceMemberus-gaap:MeasurementInputOptionVolatilityMember2020-09-300001001233sgmo:SangamoFranceMemberus-gaap:MeasurementInputOptionVolatilityMember2019-12-310001001233us-gaap:MeasurementInputPriceVolatilityMember2020-09-300001001233us-gaap:MeasurementInputPriceVolatilityMember2019-12-310001001233us-gaap:MoneyMarketFundsMember2020-09-300001001233us-gaap:CommercialPaperMember2020-09-300001001233us-gaap:CashEquivalentsMember2020-09-300001001233us-gaap:CorporateDebtSecuritiesMember2020-09-300001001233us-gaap:AssetBackedSecuritiesMember2020-09-300001001233us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2020-09-300001001233us-gaap:MoneyMarketFundsMember2019-12-310001001233us-gaap:CommercialPaperMember2019-12-310001001233us-gaap:CashEquivalentsMember2019-12-310001001233us-gaap:CorporateDebtSecuritiesMember2019-12-310001001233us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2019-12-3100010012332019-01-012019-12-310001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:NovartisInstitutesForBioMedicalResearchIncMember2020-08-012020-08-310001001233sgmo:CollaborationAndLicenseAgreementMembersrt:MaximumMembersgmo:NovartisInstitutesForBioMedicalResearchIncMembersgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember2020-07-272020-07-270001001233sgmo:CollaborationAndLicenseAgreementMembersrt:MaximumMembersgmo:AchievementOfCommercialMilestonesMembersgmo:NovartisInstitutesForBioMedicalResearchIncMember2020-07-272020-07-270001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:NovartisInstitutesForBioMedicalResearchIncMember2020-07-272020-07-270001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:NovartisInstitutesForBioMedicalResearchIncMember2020-09-300001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:NovartisInstitutesForBioMedicalResearchIncMember2020-07-012020-09-300001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:NovartisInstitutesForBioMedicalResearchIncMember2020-01-012020-09-300001001233sgmo:BiogenMAIncMembersgmo:StockPurchaseAgreementMember2020-04-082020-04-300001001233sgmo:BiogenMAIncMembersgmo:StockPurchaseAgreementMember2020-04-300001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:BiogenMAIncMember2020-05-012020-05-310001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:BiogenMAIncMember2020-02-290001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:PreApprovalMilestoneMembersgmo:BiogenMAIncMember2020-02-290001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:BiogenMAIncMembersgmo:SalesBasedMilestoneMember2020-02-29sgmo:product_target0001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:BiogenMAIncMember2020-02-012020-02-290001001233sgmo:CollaborationAndLicenseAgreementMembersrt:MaximumMembersgmo:BiogenMAIncMember2020-02-012020-02-290001001233sgmo:BiogenMAIncMembersgmo:StockPurchaseAgreementMember2020-02-012020-02-290001001233sgmo:BiogenMAIncMembersgmo:StockPurchaseAgreementMember2020-02-280001001233sgmo:BiogenMAIncMembersgmo:StockPurchaseAgreementMember2020-01-012020-09-300001001233sgmo:BiogenMAIncMembersgmo:StockPurchaseAgreementMember2020-09-300001001233sgmo:BiogenMAIncMember2020-01-012020-09-300001001233sgmo:BiogenMAIncMemberus-gaap:LicenseAndServiceMember2020-07-012020-09-300001001233sgmo:BiogenMAIncMemberus-gaap:LicenseAndServiceMember2019-07-012019-09-300001001233sgmo:BiogenMAIncMemberus-gaap:LicenseAndServiceMember2020-01-012020-09-300001001233sgmo:BiogenMAIncMemberus-gaap:LicenseAndServiceMember2019-01-012019-09-300001001233sgmo:ResearchServicesMembersgmo:BiogenMAIncMember2020-07-012020-09-300001001233sgmo:ResearchServicesMembersgmo:BiogenMAIncMember2019-07-012019-09-300001001233sgmo:ResearchServicesMembersgmo:BiogenMAIncMember2020-01-012020-09-300001001233sgmo:ResearchServicesMembersgmo:BiogenMAIncMember2019-01-012019-09-300001001233sgmo:BiogenMAIncMember2020-07-012020-09-300001001233sgmo:BiogenMAIncMember2019-07-012019-09-300001001233sgmo:BiogenMAIncMember2019-01-012019-09-300001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:BiogenMAIncMember2020-09-300001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:BiogenMAIncMember2020-01-012020-09-300001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:BiogenMAIncMember2020-07-012020-09-300001001233sgmo:BiogenMAIncMembersgmo:StockPurchaseAgreementMember2020-07-012020-09-300001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:KitePharmaIncMember2018-04-052018-04-050001001233sgmo:CollaborationAndLicenseAgreementMembersrt:MaximumMembersgmo:KitePharmaIncMember2018-04-052018-04-050001001233sgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMembersgmo:CollaborationAndLicenseAgreementMembersgmo:KitePharmaIncMember2018-04-052018-04-050001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:KitePharmaIncMembersgmo:AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember2018-04-052018-04-05sgmo:option0001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:KitePharmaIncMember2020-01-012020-09-300001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:KitePharmaIncMember2019-09-012019-09-300001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:KitePharmaIncMember2020-09-300001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:KitePharmaIncMember2019-12-310001001233sgmo:KitePharmaIncMember2020-01-012020-09-300001001233us-gaap:LicenseAndServiceMembersgmo:KitePharmaIncMember2020-07-012020-09-300001001233us-gaap:LicenseAndServiceMembersgmo:KitePharmaIncMember2019-07-012019-09-300001001233us-gaap:LicenseAndServiceMembersgmo:KitePharmaIncMember2020-01-012020-09-300001001233us-gaap:LicenseAndServiceMembersgmo:KitePharmaIncMember2019-01-012019-09-300001001233sgmo:ResearchServicesMembersgmo:KitePharmaIncMember2020-07-012020-09-300001001233sgmo:ResearchServicesMembersgmo:KitePharmaIncMember2019-07-012019-09-300001001233sgmo:ResearchServicesMembersgmo:KitePharmaIncMember2020-01-012020-09-300001001233sgmo:ResearchServicesMembersgmo:KitePharmaIncMember2019-01-012019-09-300001001233sgmo:KitePharmaIncMember2020-07-012020-09-300001001233sgmo:KitePharmaIncMember2019-07-012019-09-300001001233sgmo:KitePharmaIncMember2019-01-012019-09-300001001233sgmo:PfizerSB525Member2020-01-012020-09-300001001233sgmo:PfizerMembersgmo:SBFiveTwoFiveAndOtherProductsMember2017-05-012017-05-310001001233sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMembersrt:MaximumMembersgmo:PfizerMembersgmo:SBFiveTwoFiveAndOtherProductsMember2017-05-012017-05-310001001233srt:MaximumMembersgmo:PfizerMembersgmo:SBFiveTwoFiveAndOtherProductsMember2017-05-012017-05-310001001233srt:MaximumMembersgmo:AchievementOfFirstCommercialSaleMilestonesMembersgmo:PfizerMembersgmo:SBFiveTwoFiveAndOtherProductsMember2017-05-012017-05-310001001233sgmo:SBFiveTwoFiveMembersrt:MaximumMembersgmo:PfizerMember2017-05-310001001233sgmo:OtherProductsMembersrt:MaximumMembersgmo:PfizerMember2017-05-31sgmo:milestone0001001233sgmo:PfizerSB525Membersgmo:SBFiveTwoFiveAndOtherProductsMember2020-09-300001001233sgmo:PfizerSB525Membersgmo:SBFiveTwoFiveAndOtherProductsMember2017-05-012020-09-30sgmo:product0001001233sgmo:PfizerSB525Membersgmo:SBFiveTwoFiveAndOtherProductsMember2020-01-012020-09-300001001233sgmo:PfizerMember2020-09-300001001233sgmo:PfizerMember2019-12-310001001233sgmo:PfizerMember2019-12-012019-12-310001001233sgmo:PfizerMember2020-01-012020-09-300001001233sgmo:PfizerSB525Membersgmo:AmendedCollaborationAndLicenseAgreementMember2020-09-300001001233us-gaap:SubsequentEventMembersgmo:PfizerMembersrt:ScenarioForecastMembersgmo:PhaseThreeClinicalTrialMember2020-10-012020-10-300001001233sgmo:PfizerMembersgmo:PhaseThreeClinicalTrialMember2020-09-300001001233sgmo:PfizerSB525Membersgmo:AmendedCollaborationAndLicenseAgreementMembersgmo:PhaseThreeClinicalTrialMember2020-09-300001001233sgmo:PfizerSB525Memberus-gaap:LicenseAndServiceMember2020-07-012020-09-300001001233sgmo:PfizerSB525Memberus-gaap:LicenseAndServiceMember2019-07-012019-09-300001001233sgmo:PfizerSB525Memberus-gaap:LicenseAndServiceMember2020-01-012020-09-300001001233sgmo:PfizerSB525Memberus-gaap:LicenseAndServiceMember2019-01-012019-09-300001001233sgmo:PfizerSB525Membersgmo:MilestoneAchievementMember2020-07-012020-09-300001001233sgmo:PfizerSB525Membersgmo:MilestoneAchievementMember2019-07-012019-09-300001001233sgmo:PfizerSB525Membersgmo:MilestoneAchievementMember2020-01-012020-09-300001001233sgmo:PfizerSB525Membersgmo:MilestoneAchievementMember2019-01-012019-09-300001001233sgmo:PfizerSB525Member2020-07-012020-09-300001001233sgmo:PfizerSB525Member2019-07-012019-09-300001001233sgmo:PfizerSB525Member2019-01-012019-09-300001001233sgmo:PfizerMember2019-01-012019-09-300001001233sgmo:PfizerMember2020-03-012020-03-310001001233sgmo:PfizerMember2017-12-012017-12-310001001233srt:MaximumMembersgmo:CNineORFSevenTwoMembersgmo:PfizerMembersgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember2017-12-012017-12-310001001233srt:MaximumMembersgmo:AchievementOfCommercialMilestonesMembersgmo:CNineORFSevenTwoMembersgmo:PfizerMember2017-12-012017-12-310001001233sgmo:CNineORFSevenTwoMembersgmo:PfizerMember2017-12-012017-12-310001001233sgmo:CNineORFSevenTwoMembersgmo:PfizerMember2020-09-300001001233sgmo:CNineORFSevenTwoMembersgmo:PfizerMember2019-12-310001001233sgmo:CNineORFSevenTwoMembersgmo:PfizerMember2020-09-012020-09-300001001233sgmo:CNineORFSevenTwoMembersgmo:PfizerMember2020-07-012020-09-300001001233sgmo:CNineORFSevenTwoMembersgmo:PfizerMember2020-01-012020-09-300001001233sgmo:PfizerMemberus-gaap:LicenseAndServiceMember2020-07-012020-09-300001001233sgmo:PfizerMemberus-gaap:LicenseAndServiceMember2019-07-012019-09-300001001233sgmo:PfizerMemberus-gaap:LicenseAndServiceMember2020-01-012020-09-300001001233sgmo:PfizerMemberus-gaap:LicenseAndServiceMember2019-01-012019-09-300001001233sgmo:MilestoneAchievementMembersgmo:PfizerMember2020-07-012020-09-300001001233sgmo:MilestoneAchievementMembersgmo:PfizerMember2019-07-012019-09-300001001233sgmo:MilestoneAchievementMembersgmo:PfizerMember2020-01-012020-09-300001001233sgmo:MilestoneAchievementMembersgmo:PfizerMember2019-01-012019-09-300001001233sgmo:PfizerMember2020-07-012020-09-300001001233sgmo:PfizerMember2019-07-012019-09-30sgmo:program0001001233sgmo:SanofiMember2014-01-012014-01-310001001233sgmo:SanofiMember2020-01-012020-09-300001001233sgmo:AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMembersgmo:CollaborationAndLicenseAgreementMembersrt:MaximumMembersgmo:SanofiMember2014-01-012014-01-310001001233sgmo:AchievementOfSpecifiedSalesMilestonesMembersgmo:CollaborationAndLicenseAgreementMembersrt:MaximumMembersgmo:SanofiMember2014-01-012014-01-310001001233sgmo:CollaborationAndLicenseAgreementMembersrt:MaximumMembersgmo:SanofiMember2014-01-012014-01-310001001233sgmo:SanofiMember2019-09-300001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:MilestoneTwoMembersgmo:SanofiMember2019-09-300001001233sgmo:SanofiMember2014-01-012020-09-300001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:SanofiMember2014-01-012020-09-300001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:SanofiMember2014-01-012014-01-310001001233sgmo:MilestoneThreeMembersgmo:CollaborationAndLicenseAgreementMembersgmo:SanofiMember2020-09-300001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:SanofiMember2020-09-300001001233sgmo:CollaborationAndLicenseAgreementMembersgmo:SanofiMember2019-12-310001001233sgmo:ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMembersgmo:CollaborationAndLicenseAgreementMembersgmo:SanofiMember2019-08-012019-08-310001001233sgmo:ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMembersgmo:CollaborationAndLicenseAgreementMembersgmo:SanofiMember2020-09-300001001233us-gaap:LicenseAndServiceMembersgmo:SanofiMember2020-07-012020-09-300001001233us-gaap:LicenseAndServiceMembersgmo:SanofiMember2019-07-012019-09-300001001233us-gaap:LicenseAndServiceMembersgmo:SanofiMember2020-01-012020-09-300001001233us-gaap:LicenseAndServiceMembersgmo:SanofiMember2019-01-012019-09-300001001233sgmo:ResearchServicesMembersgmo:SanofiMember2020-07-012020-09-300001001233sgmo:ResearchServicesMembersgmo:SanofiMember2019-07-012019-09-300001001233sgmo:ResearchServicesMembersgmo:SanofiMember2020-01-012020-09-300001001233sgmo:ResearchServicesMembersgmo:SanofiMember2019-01-012019-09-300001001233sgmo:MilestoneAchievementMembersgmo:SanofiMember2020-07-012020-09-300001001233sgmo:MilestoneAchievementMembersgmo:SanofiMember2019-07-012019-09-300001001233sgmo:MilestoneAchievementMembersgmo:SanofiMember2020-01-012020-09-300001001233sgmo:MilestoneAchievementMembersgmo:SanofiMember2019-01-012019-09-300001001233sgmo:SanofiMember2020-07-012020-09-300001001233sgmo:SanofiMember2019-07-012019-09-300001001233sgmo:SanofiMember2019-01-012019-09-300001001233sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember2018-05-012018-05-310001001233us-gaap:GrantMembersgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember2020-01-012020-09-300001001233sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember2020-09-300001001233sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember2019-12-31utr:sqft0001001233sgmo:BrisbaneCaliforniaMembersgmo:OfficeAndLaboratoryMember2020-09-300001001233sgmo:PropertySubjectToOperatingLeaseOneMembersgmo:RichmondCaliforniaMembersgmo:OfficeAndLaboratoryMember2020-09-300001001233sgmo:PropertySubjectToOperatingLeaseOneMembersgmo:ResearchAndOfficeSpaceMembersgmo:ValbonneFranceMember2020-09-300001001233srt:MinimumMember2020-09-300001001233srt:MaximumMember2020-09-300001001233sgmo:RichmondCaliforniaMember2020-05-310001001233sgmo:BrammerBioMAMember2020-09-300001001233sgmo:LonzaNetherlandsBVMember2020-09-300001001233us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300001001233us-gaap:ResearchAndDevelopmentExpenseMember2019-07-012019-09-300001001233us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300001001233us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-09-300001001233us-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-09-300001001233us-gaap:GeneralAndAdministrativeExpenseMember2019-07-012019-09-300001001233us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-09-300001001233us-gaap:GeneralAndAdministrativeExpenseMember2019-01-012019-09-300001001233us-gaap:CommonStockMember2019-04-012019-04-300001001233us-gaap:CommonStockMember2019-04-3000010012332019-04-012019-04-300001001233sgmo:AtTheMarketOfferingAgreementMembersgmo:JefferiesLLCMember2020-08-052020-08-050001001233sgmo:AtTheMarketOfferingAgreementMembersgmo:JefferiesLLCMember2020-08-050001001233sgmo:AtTheMarketOfferingAgreementMembersrt:MaximumMembersgmo:JefferiesLLCMember2020-08-052020-08-050001001233sgmo:AtTheMarketOfferingAgreementMembersgmo:JefferiesLLCMember2020-01-012020-09-300001001233sgmo:SangamoFranceMember2018-10-012018-10-010001001233sgmo:SangamoFranceMember2018-10-012018-11-230001001233sgmo:SangamoFranceMember2018-12-310001001233sgmo:SharePurchaseAgreementAndTenderOfferAgreementMembersgmo:SangamoFranceMember2018-01-012018-09-300001001233sgmo:SharePurchaseAgreementAndTenderOfferAgreementMembersgmo:SangamoFranceMember2019-12-310001001233sgmo:SharePurchaseAgreementAndTenderOfferAgreementMembersrt:ExecutiveOfficerMembersgmo:SangamoFranceMember2020-01-012020-09-300001001233sgmo:SharePurchaseAgreementAndTenderOfferAgreementMembersgmo:SangamoFranceMember2020-09-300001001233sgmo:SharePurchaseAgreementAndTenderOfferAgreementMemberus-gaap:ValuationTechniqueOptionPricingModelMembersgmo:SangamoFranceMember2018-10-010001001233sgmo:SharePurchaseAgreementAndTenderOfferAgreementMembersgmo:SangamoFranceMember2020-09-300001001233sgmo:SangamoFranceMember2018-10-01
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________________________
FORM 10-Q
________________________________________________
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2020
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             
Commission file number 000-30171
________________________________________________
SANGAMO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
________________________________________________
Delaware68-0359556
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
  
7000 Marina Blvd., Brisbane, California, 94005
(Address of principal executive offices) (Zip Code)
(510) 970-6000
(Registrant’s telephone number, including area code)
________________________________________________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareSGMONasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes        No   ☒
As of October 30, 2020, 141,441,378 shares of the issuer’s common stock, par value $0.01 per share, were outstanding.



Table of Contents
INDEX
SANGAMO THERAPEUTICS, INC.
Unless otherwise indicated or the context suggests otherwise, references in this Quarterly Report on Form 10-Q, or Quarterly Report, to “Sangamo,” “the Company,” “we,” “us,” and “our” refer to Sangamo Therapeutics, Inc. and our subsidiaries, including Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) and Sangamo Therapeutics UK Ltd.
Any third-party trade names, trademarks and service marks appearing in this Quarterly Report are the property of their respective holders.
2

Table of Contents
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Some statements contained in this report are forward-looking with respect to our operations, research, development and commercialization activities, clinical trials, operating results and financial condition. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements about:
our strategy;
anticipated product candidate development and potential commercialization of any resulting products;
the initiation, scope, rate of progress, enrollment, anticipated results and timing of our preclinical studies and clinical trials and those of our collaborators or strategic partners;
the therapeutic and commercial potential of technologies used by us in our product candidates, including our zinc finger protein, or ZFP, technology platform, zinc finger nucleases, or ZFNs, and ZFP transcription factors, or ZFP-TFs;
the expected benefits of the acquisition of Sangamo Therapeutics France S.A.S., or Sangamo France;
our ability to establish and maintain collaborations and strategic partnerships and realize the expected benefits of such arrangements;
anticipated revenues from existing and new collaborations and the timing thereof;
our estimates regarding the impact of the evolving COVID-19 pandemic on our business and operations and the business and operations of our collaborators, including clinical trials and manufacturing, and our ability to manage such impacts;
our research and development and other expenses;
our ability to obtain adequate preclinical and clinical supplies of our product candidates from current and potential new suppliers and manufacturers;
the ability of Sangamo and our collaborators and strategic partners to obtain and maintain regulatory approvals for product candidates;
our ability to comply with, and the impact of, regulatory requirements, obligations and restrictions on our business and operations;
our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, including our ability to obtain rights to the gene transfer technologies required to develop and commercialize our product candidates;
our estimates regarding the sufficiency of our cash resources and our expenses, capital requirements and need for additional financing, and our ability to obtain additional financing;
our ability to manage the growth of our business;
our projected operating and financial performance;
our operational and legal risks; and
our plans, objectives, expectations and intentions and any other statements that are not historical facts.
In some cases, you can identify forward-looking statements by terms such as: “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “seeks,” “should” and “will” and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Quarterly Report. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q.
3

Table of Contents
PART I. FINANCIAL INFORMATION
ITEM 1.    FINANCIAL STATEMENTS
SANGAMO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited; in thousands)
September 30,
2020
December 31,
2019
ASSETS
Current assets:
Cash and cash equivalents$259,393 $80,428 
Marketable securities389,434 282,046 
Interest receivable822 682 
Accounts receivable39,487 36,909 
Prepaid expenses and other current assets11,158 5,408 
Total current assets700,294 405,473 
Marketable securities, non-current45,761 21,832 
Property and equipment, net35,282 29,926 
Intangible assets55,569 53,156 
Goodwill40,984 39,273 
Operating lease right-of-use assets71,637 77,289 
Other non-current assets12,683 9,067 
Restricted cash1,500 1,500 
Total assets$963,710 $637,516 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities$17,897 $17,556 
Accrued compensation and employee benefits17,873 13,605 
Deferred revenues87,791 38,711 
Total current liabilities123,561 69,872 
Deferred revenues, non-current267,903 81,432 
Long-term portion of lease liabilities38,259 41,192 
Deferred income tax6,868 6,570 
Other non-current liabilities6,238 5,711 
Total liabilities442,829 204,777 
Commitments and contingencies
Stockholders' equity:
Preferred stock  
Common stock1,412 1,160 
Additional paid-in capital1,255,823 1,090,828 
Accumulated deficit(737,377)(656,985)
Accumulated other comprehensive income (loss)1,553 (2,449)
Total Sangamo Therapeutics, Inc. stockholders' equity521,411 432,554 
Non-controlling interest(530)185 
Total stockholders' equity520,881 432,739 
Total liabilities and stockholders' equity$963,710 $637,516 
See accompanying Notes to Condensed Consolidated Financial Statements.
4

Table of Contents
SANGAMO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited; in thousands, except per share amounts)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2020201920202019
Revenues$57,763 $21,958 $92,392 $47,577 
Operating expenses:
Research and development45,287 36,288 128,289 107,593 
General and administrative16,177 14,918 50,223 46,633 
Total operating expenses61,464 51,206 178,512 154,226 
Loss from operations(3,701)(29,248)(86,120)(106,649)
Interest and other income, net2,430 1,887 5,910 6,729 
Loss before taxes(1,271)(27,361)(80,210)(99,920)
Income tax expense(237) (237) 
Net loss(1,508)(27,361)(80,447)(99,920)
Net income (loss) attributable to non-controlling interest42 (54)(55)(179)
Net loss attributable to Sangamo Therapeutics, Inc. stockholders$(1,550)$(27,307)$(80,392)$(99,741)
Basic and diluted net loss per share attributable to Sangamo
   Therapeutics, Inc. stockholders
$(0.01)$(0.24)$(0.61)$(0.90)
Shares used in computing basic and diluted net loss per share
attributable to Sangamo Therapeutics, Inc. stockholders
141,100 115,710 132,079 110,837 
See accompanying Notes to Condensed Consolidated Financial Statements.
5

Table of Contents
SANGAMO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(Unaudited; in thousands)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2020201920202019
Net loss$(1,508)$(27,361)$(80,447)$(99,920)
Foreign currency translation adjustment3,839 (4,077)3,989 (4,139)
Change in unrealized (loss) gain on available-for-sale securities(633)(59)13 678 
Comprehensive income (loss)1,698 (31,497)(76,445)(103,381)
Comprehensive income (loss) attributable to non-controlling interest42 (54)(55)(179)
Comprehensive income (loss) attributable to Sangamo Therapeutics, Inc.$1,656 $(31,443)$(76,390)$(103,202)
See accompanying Notes to Condensed Consolidated Financial Statements.
6

Table of Contents
SANGAMO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited; in thousands, except share amounts)

Three Months Ended September 30, 2020
Common StockAdditional
Paid-in
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Income
Non-
Controlling
Interest
Total
Stockholders'
Equity
SharesAmount
Balances at June 30, 2020140,973,277 $1,410 $1,247,527 $(735,827)$(1,653)$(251)$511,206 
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax
239,553 2 1,614 — — — 1,616 
Stock-based compensation— — 6,682 — — — 6,682 
Acquisition of additional shares of
Sangamo France
— — — — — (321)(321)
Foreign currency translation adjustment
— — — — 3,839 — 3,839 
Net unrealized loss on marketable securities— — — — (633)— (633)
Net (loss) income— — — (1,550)— 42 (1,508)
Balances at September 30, 2020141,212,830 $1,412 $1,255,823 $(737,377)$1,553 $(530)$520,881 

Nine Months Ended September 30, 2020
Common StockAdditional
Paid-in
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Loss
Non-
Controlling
Interest
Total
Stockholders'
Equity
SharesAmount
Balance at December 31, 2019115,972,708 $1,160 $1,090,828 $(656,985)$(2,449)$185 $432,739 
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax
648,660 6 2,462 — — 2,468 
Issuance of common stock under
employee stock purchase plan
171,305 2 1,185 — — — 1,187 
Issuance of common stock in
connection with the Biogen
collaboration agreement, net of
issuance costs
24,420,157 244 142,282 — — — 142,526 
Acquisition of additional shares of
Sangamo France
— — — — (660)(660)
Stock-based compensation— — 19,066 — — 19,066 
Foreign currency translation adjustment
— — — — 3,989 — 3,989 
Net unrealized gain on marketable securities
— — — — 13 — 13 
Net loss
— — — (80,392)— (55)(80,447)
Balances at September 30, 2020141,212,830 $1,412 $1,255,823 $(737,377)$1,553 $(530)$520,881 
See accompanying Notes to Condensed Consolidated Financial Statements.
7

Table of Contents
SANGAMO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited; in thousands, except share amounts)
Three Months Ended September 30, 2019
Common StockAdditional
Paid-in
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Loss
Non-
Controlling
Interest
Total
Stockholders'
Equity
SharesAmount
Balance at June 30, 2019115,603,096 $1,156 $1,078,976 $(634,233)$(765)$614 $445,748 
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax
166,902 2 702 — — — 704 
Issuance of common stock under public offering, net of issuance costs— — (321)(321)
Issuance costs related to Sangamo France Acquisition— — (7)— — — (7)
Stock-based compensation— — 4,701 — — — 4,701 
Foreign currency translation adjustment
— — — — (4,077)— (4,077)
Net unrealized loss on marketable securities— — — — (59)— (59)
Net loss
— — — (27,307)— (54)(27,361)
Balances at September 30, 2019115,769,998 $1,158 $1,084,372 $(661,540)$(4,901)$239 $419,328 

Nine Months Ended September 30, 2019
Common StockAdditional
Paid-in
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Loss
Non-
Controlling
Interest
Total
Stockholders'
Equity
SharesAmount
Balances at December 31, 2018102,187,471 $1,022 $929,632 $(562,696)$(1,440)$739 $367,257 
Cumulative-effect adjustment of ASC Topic 842 on January 1, 2019
— — — 897 — — 897 
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax
800,818 8 3,355 — — — 3,363 
Issuance of common stock under employee stock purchase plan131,709 1 1,138 — — — 1,139 
Issuance of common stock under public offering, net of issuance costs12,650,000 127 136,181 — — — 136,308 
Acquisition of additional shares of Sangamo France— — — — — (321)(321)
Issuance costs related to Sangamo France Acquisition— — (25)— — — (25)
Stock-based compensation— — 14,091 — — — 14,091 
Foreign currency translation adjustment
— — — — (4,139)— (4,139)
Net unrealized gain on marketable securities
— — — — 678 — 678 
Net loss
— — — (99,741)— (179)(99,920)
Balances at September 30, 2019115,769,998 $1,158 $1,084,372 $(661,540)$(4,901)$239 $419,328 
See accompanying Notes to Condensed Consolidated Financial Statements.
8

Table of Contents
SANGAMO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited; in thousands)
Nine Months Ended
September 30,
20202019
Operating Activities:
Net loss$(80,447)$(99,920)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization3,999 2,742 
Amortization of discount on marketable securities(1,344)(3,715)
Amortization and other changes in operating lease right-of-use assets5,706 3,796 
Gain on free shares(31)(488)
Stock-based compensation19,066 14,091 
Loss on disposal of property and equipment197  
Net loss on lease termination 218 
Other (29)
Net changes in operating assets and liabilities:
Interest receivable(140)(305)
Accounts receivable(2,578)(17,280)
Prepaid expenses and other assets(9,098)(4,734)
Accounts payable and accrued liabilities1,336 (1,753)
Accrued compensation and employee benefits4,186 1,608 
Deferred revenues235,551 (20,477)
Long-term portion of lease liabilities(2,760)(920)
Other non-current liabilities527 3,580 
Net cash provided by (used in) operating activities174,170 (123,586)
Investing Activities:
Purchases of marketable securities(335,002)(321,390)
Maturities of marketable securities205,039 292,147 
Purchases of property and equipment(10,703)(13,894)
Purchase of additional shares of Sangamo France(503)(262)
Net cash used in investing activities(141,169)(43,399)
Financing Activities:
Proceeds from public offering of common stock, net of issuance costs 136,308 
Proceeds from issuance of common stock in connection with the Biogen collaboration agreement, net of issuance costs142,526  
Taxes paid related to net share settlement of equity awards(573)(388)
Proceeds from exercise of stock options and restricted stock units3,041 3,751 
  Proceeds from issuance of common stock under employee stock purchase plan1,187 1,139 
Net cash provided by financing activities146,181 140,810 
Effect of exchange rate changes on cash, cash equivalents, and restricted cash(217)48 
Net increase (decrease) in cash, cash equivalents, and restricted cash178,965 (26,127)
Cash, cash equivalents, and restricted cash, beginning of period81,928 143,918 
Cash, cash equivalents, and restricted cash, end of period$260,893 $117,791 
Supplemental disclosure of non-cash activities:
Property and equipment included in unpaid liabilities$899 $4,257 
Right-of-use assets obtained in exchange for lease obligations$ $29,647 
See accompanying Notes to Condensed Consolidated Financial Statements.

9

Table of Contents
SANGAMO THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2020
(Unaudited)
NOTE 1—ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Business Overview
Sangamo Therapeutics, Inc. (“Sangamo” or “the Company”) was incorporated in the State of Delaware in June 1995. Sangamo is a clinical stage biotechnology company focused on translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using the Company's platform technologies in gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing and in vivo genome regulation.
Basis of Presentation
The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. The Condensed Consolidated Balance Sheet data at December 31, 2019 was derived from the audited Consolidated Financial Statements included in Sangamo’s Annual Report on Form 10-K for the year ended December 31, 2019 (the “2019 Annual Report”) as filed with the SEC on February 28, 2020.
The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or are exposed to less than 100% of the economics, the Company records net income (loss) attributable to non-controlling interests on the Company's Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.
The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December 31, 2019, included in the 2019 Annual Report.
Going Concern
Sangamo is currently working on a number of long-term development projects that will involve experimental technology. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaboration funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and marketable securities as of September 30, 2020, when combined with expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its currently planned operations through at least the next 12 months from the date these financial statements are issued. Sangamo may require additional financial resources to complete the development and commercialization of its products including zinc finger protein (“ZFP”) therapeutic products. Additional capital may not be available on terms acceptable to the Company, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company’s business and ability to advance its product candidate pipeline would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company’s stockholders, and any debt financing may include covenants that restrict the Company’s business.
Summary of Significant Accounting Policies
Use of Estimates
The preparation of these Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and
10

Table of Contents
other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.
During the three months ended March 31, 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the collaboration agreement with Sanofi Genzyme (“Sanofi”) as a result of a decision made by the joint steering committee of Sanofi and Sangamo to increase the project scope and related project cost, which resulted in a decrease in the measure of proportional cumulative performance. The Company also recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia A collaboration agreement with Pfizer Inc. (“Pfizer”). This adjustment was a direct result of the decision to decrease the project scope and the corresponding costs after the successful investigational new drug application (“IND”) transfer of the SB-525 product candidate to Pfizer, both of which resulted in an increase in the measure of proportional cumulative performance.
During the nine months ended September 30, 2020, the Company recorded adjustments to revenue related to changes in estimates in connection with the C9ORF72 research collaboration and license agreement with Pfizer. These adjustments were a direct result of the decision to decrease the project scope and the corresponding costs due to advancement of the program, which resulted in an increase in the measure of proportional cumulative performance.
The Pfizer-related adjustment in September 2020 increased revenue by $5.8 million, decreased net loss by $5.8 million and decreased the Company’s basic net loss per share by $0.04 for the three months ended September 30, 2020.
The Pfizer and Sanofi-related adjustments increased revenue by $8.9 million, decreased net loss by $8.9 million and decreased the Company’s basic net loss per share by $0.06 for the nine months ended September 30, 2020.
Revenue Recognition
The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC Topic 606”). The Company’s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee’s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo’s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.
In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.
A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company’s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e. cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and
11

Table of Contents
manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company’s current assumptions regarding the timing of its deliverables.
As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.
Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Pfizer68 %16 %51 %11 %
Biogen16 % 19 % 
Kite Pharma, Inc.13 %40 %24 %55 %
Sanofi3 %40 %4 %29 %

Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. As of September 30, 2020, the Company had not incurred any losses related to these receivables.
Funds received from third parties under contract or funds received from grant arrangements are generally recorded as revenue if the Company is deemed to be the principal participant in the arrangements because the activities under the contracts or grants are part of the Company’s development programs. Contract funds are not refundable and are recognized when the related qualified research and development costs are incurred and there is reasonable assurance that the funds will be received. Funds received in advance are recorded as deferred revenue.
Business Combinations
The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (“IPR&D”) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition be recorded at their fair values as of the acquisition date on the Company’s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.
Goodwill and Intangible Assets
Goodwill represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts. As of September 30, 2020, no impairment of goodwill or indefinite-lived intangible assets has been identified.
Valuation of Long-Lived Assets
Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. As of September 30, 2020, no impairment of any long-lived assets has been identified.
12

Table of Contents
Fair Value Measurements
The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free shares asset/liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed to approximate fair value.
Cash, Cash Equivalents and Restricted Cash
Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and commercial paper. Restricted cash consists of a letter of credit for $1.5 million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.
A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):
September 30,
2020
December 31,
2019
September 30,
2019
December 31,
2018
 Cash and cash equivalents$259,393 $80,428 $114,291 $140,418 
 Current restricted cash  2,000  
 Non-current restricted cash1,500 1,500 1,500 3,500 
Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows$260,893 $81,928 $117,791 $143,918 
Marketable Securities
Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in Accumulated Other Comprehensive Income (Loss) (“AOCI”) within stockholders' equity.
The Company’s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. If the estimated fair value of a security is below its carrying value, the Company evaluates whether it is more likely than not that it will sell the security before its anticipated recovery in market value and whether evidence indicating that the cost of the investment is recoverable within a reasonable period of time outweighs evidence to the contrary. The Company also evaluates whether or not it intends to sell the investment. If the impairment is considered to be other-than-temporary, the security is written down to its estimated fair value. In addition, the Company considers whether credit losses exist for any securities. A credit loss exists if the present value of cash flows expected to be collected is less than the amortized cost basis of the security. Other-than-temporary declines in estimated fair value and credit losses are included in other income (expense) within the accompanying Condensed Consolidated Statements of Operations. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the estimated fair value has been less than the Company’s cost basis, the financial condition and near-term prospects of the investee and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in interest and other income, net, which are determined using the specific identification method.
Concentrations of Risk
Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Condensed Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established policies relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the Condensed Consolidated Balance Sheets.
Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an IND application filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material
13

Table of Contents
from the Company’s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.
Leases
The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.
As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company’s operating leases is recognized on a straight-line basis over the lease term.
The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.
Foreign Currency Translation
The functional currency of the Company’s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders’ equity. Revenues and expenses from the Company’s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company’s Condensed Consolidated Statements of Operations.
Recent Adopted Accounting Pronouncements
Collaborative Arrangements
In November 2018, the FASB issued Accounting Standards Update (“ASU”) 2018-18, Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 (“ASU 2018-18”), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASU 2018-18 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. ASU 2018-18 is effective for all interim and annual reporting periods beginning after December 15, 2019. On January 1, 2020, the Company adopted ASU 2018-18. The adoption of ASU 2018-18 did not have a material impact on the Company's Condensed Consolidated Financial Statements.
Goodwill Impairment Testing
In January 2017, the FASB issued ASU No. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment (“ASU 2017-04”). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. ASU 2017-04 requires goodwill impairment to be measured as the amount by which a reporting unit’s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU 2017-04 requires prospective application and is effective for annual periods beginning after December 15, 2019. ASU 2017-04 will require the Company to amend its methodology for determining any goodwill impairment beginning in 2020. On January 1, 2020, the Company adopted ASU 2017-04. The adoption of ASU 2017-04 did not have a material impact on the Company's Condensed Consolidated Financial Statements.
Credit Losses
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326) (“ASU 2016-13”). ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit
14

Table of Contents
losses. ASU 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted. On January 1, 2020, the Company adopted ASU 2016-13 by using a modified retrospective approach. The adoption of ASU 2016-13 did not have a material impact on the Company's Condensed Consolidated Financial Statements.
Income Taxes
In December 2019, the FASB issued ASU No. 2019-12, Income Taxes – Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The guidance removes exceptions to the general principles in Income Taxes (Topic 740) for allocating tax expense between financial statement components, accounting basis differences stemming from an ownership change in foreign investments and interim period income tax accounting for year-to-date losses that exceed projected losses. The guidance becomes effective for annual reporting periods beginning after December 15, 2020 and interim periods within those fiscal years with early adoption permitted. On January 1, 2020, the Company early adopted ASU 2019-12. The adoption of ASU 2019-12 did not have a material impact on the Company's Condensed Consolidated Financial Statements.
NOTE 2—FAIR VALUE MEASUREMENTS
The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, available-for-sale marketable securities and the free shares asset. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:
Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).
The fair value measurements of the Company’s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):
September 30, 2020
Fair Value Measurements
TotalLevel 1Level 2Level 3
Assets:
Cash equivalents:
Money market funds$172,508 $172,508 $ $ 
Commercial paper securities5,999  5,999  
Total178,507 172,508 5,999  
Marketable securities:
Commercial paper securities238,398  238,398  
Corporate debt securities122,484  122,484  
Asset-backed securities13,066  13,066  
U.S. government-sponsored entity debt securities61,247  61,247  
Total435,195  435,195  
Total cash equivalents and marketable securities$613,702 $172,508 $441,194 $ 
Free shares asset$129 $ $ $129 

15

Table of Contents
December 31, 2019
Fair Value Measurements
TotalLevel 1Level 2Level 3
Assets:
Cash equivalents:
Money market funds$30,496 $30,496 $ $ 
 Commercial paper securities 2,999  2,999  
Total33,495 30,496 2,999  
Marketable securities:
Commercial paper securities155,368  155,368  
Corporate debt securities95,017  95,017  
U.S. government-sponsored entity debt securities53,493  53,493  
Total303,878  303,878  
Total cash equivalents and marketable securities$337,373 $30,496 $306,877 $ 
Free shares asset$236 $ $ $236 
Cash Equivalents and Marketable Securities
The Company generally classifies its marketable securities and some cash equivalents as Level 2. Instruments are classified as Level 2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including, listed in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.
Free Shares Asset
As a result of the July 20, 2018 Share Purchase Agreement (“Sangamo France SPA”) to acquire Sangamo France (see Note 10 — Acquisition of Sangamo Therapeutics France S.A.S.), the Company entered into arrangements with the holders of approximately 477,000 “free shares” of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option). The Company initially recorded a liability of $0.2 million on the acquisition date. The put options were classified within Level 3 of the fair value hierarchy as the Company utilized a binomial-lattice pricing model (the “Monte Carlo simulation model”) that involved certain market conditions to estimate the fair value of the options. The assumptions used in this simulation model are reviewed on a quarterly basis and adjusted, as needed. Subsequent changes in the fair value of the free shares are recorded in general and administrative expenses in the Condensed Consolidated Statements of Operations. The Company purchased approximately 111,000 shares during 2019 and 228,000 shares during the nine months ended September 30, 2020, of the 477,000 total free shares, for a cash payment of approximately $0.3 million and $0.5 million respectively, upon exercise of the put options. As of September 30, 2020, approximately 138,000 free shares remain outstanding and subject to purchase by the Company.
The fair value of the free shares' asset was approximately $0.2 million at December 31, 2019. The Company recognized an immaterial increase in the fair value of the free shares, offset by approximately $0.1 million for the shares purchased during the nine months ended September 30, 2020, resulting in an asset balance of approximately $0.1 million at September 30, 2020.
16

Table of Contents
Free Shares valuation assumptionsSeptember 30,
2020
December 31, 2019
Sangamo stock price (USD)$10.31 $8.68
Sangamo France stock price (EUR)2.55 2.14
EUR / USD exchange rate0.84 0.91
Estimated correlation Sangamo and Sangamo France stock prices100.0%100.0%
Sangamo stock price (USD) volatility estimate65.7%72.5%
Sangamo France stock price (EUR) volatility estimate65.7%72.5%
EUR / USD exchange rate volatility estimate6.4%6.6%
Risk free rate and cost of debt by expected exercise dateVariesVaries

17

Table of Contents
NOTE 3—CASH EQUIVALENTS AND MARKETABLE SECURITIES
Cash Equivalents and Marketable Securities
The table below summarizes the Company’s cash equivalents and marketable securities (in thousands):
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
(Losses)
Estimated
Fair Value
September 30, 2020
Assets
Cash equivalents:
Money market funds$172,508 $ $ $172,508 
Commercial paper securities5,998 1  5,999 
Total178,506 1  178,507 
Marketable securities:
Commercial paper securities238,248 169 (19)238,398 
Corporate debt securities122,364 156 (36)122,484 
Asset-backed securities13,067 3 (4)13,066 
U.S. government-sponsored entity debt securities61,171 76  61,247 
Total434,850 404 (59)435,195 
Total cash equivalents and marketable securities$613,356 $405 $(59)$613,702 
December 31, 2019
Assets